AHA Post Conference Perspectives: Emerging Therapies in Hypertrophic Cardiomyopathy (HCM)

January 11, 2021

An expert in the management of hypertrophic cardiomyopathy discusses the burden of disease, existing treatment options, unmet needs, and explores data from an emerging class of agents, myosin inhibitors.